Dementia with Lewy bodies and Parkinson disease with dementia

The article by Thomas et al. validated 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of autopsy-proven dementia with Lewy bodies (DLB). [1] The authors depicted 3 patients with DLB who met pathologic criteria for LBD but had normal 123I-FP-CIT imaging. [1] Although further description concerning severity of parkinsonism remains unclear, these patients may not have severe parkinsonism.

Calcium Supplements May Be Associated with an Increased Risk for Dementia, Study Finds

Researchers reported an associated risk between calcium supplementation and the development of dementia in women with cerebrovascular disease. But the study authors and independent experts said the five-year population-based study sample was too small and the findings are premature and need to be replicated in a larger study.

Calcium supplements may raise the risk of dementia in elderly women with cerebrovascular disease,

Aerobic Exercise Found to Improve Cognition in Mild Vascular Cognitive Impairment

Investigators reported that, in a randomized controlled trial, patients with vascular cognitive impairment showed improvement on cognitive tests after participating in a six-month exercise program. Independent experts said the findings were promising, but preliminary.

Progressive aerobic-exercise training for six months appeared to improve cognition in adults with mild subcortical ischemic vascular cognitive impairment,

Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases

Objective: To determine whether cognitive impairment in Parkinson disease (PD) and Alzheimer disease (AD) derives from the same network pathology.

Methods: We analyzed 18F-fluorodeoxyglucose PET scans from 40 patients with AD and 40 age-matched healthy controls from the Alzheimer’s Disease Neuroimaging Initiative and scanned an additional 10 patients with AD and 10 healthy controls at The Feinstein Institute for Medical Research to derive an AD-related metabolic pattern (ADRP) analogous to our previously established PD cognition-related pattern (PDCP) and PD motor-related pattern (PDRP).

Thalamo-cortical network activity during spontaneous migraine attacks

Objective: We used MRI to search for changes in thalamo-cortical networks and thalamic microstructure during spontaneous migraine attacks by studying at the same time structure with diffusion tensor imaging and resting state function in interconnected brain networks with independent component analysis.

Methods: Thirteen patients with untreated migraine without aura (MI) underwent 3T MRI scans during an attack and were compared to a group of 19 healthy controls (HC).

Dementia with Lewy Bodies (DLB) Research Study…Complete

Dementia with Lewy Bodies (DLB) affects over 1 million people in the United States. It is caused by the buildup of abnormal protein clusters, known as “Lewy Bodies,” within the brain and is characterized by fluctuations in cognitive ability, particularly alertness and attention. Many dementia with Lewy Bodies patients also have visual hallucinations and REM sleep behavior disorder.

Parkinson’s Research Study…Complete

Most individuals with Parkinson’s disease use levodopa as treatment. It is usually taken in pill form, however long-term usage can lessen the effectiveness of the drug leading to off episodes. In these off episodes, individuals with Parkinson’s suffer from slowness, stiffness and tremors. CVT-301, the medication being evaluated in this study, is a powder form [...]
Eisai / Mild Cognitive Impairment or Mild Alzheimer’s Disease

Eisai / Mild Cognitive Impairment or Mild Alzheimer’s Disease…Complete

What is Mild Cognitive Impairment (MCI)?

Mild Cognitive Impairment is a condition in which a person has memory loss or thinking problems that are worse than those caused by normal aging, but not bad enough to interfere with daily activities.  A person with MCI has a higher risk of developing Alzheimer’s disease,

Mild to Moderate Alzheimer’s Disease Treated with Donepezil…Complete

Randomized, double-blind, placebo-controlled, fixed dose study of Lu AE58054 in patients with mild to moderate Alzheimer’s disease treated with Donepezil.

This is a 28 week study in which qualified participants will take the investigational medication or placebo ( a dummy capsule without an active ingredient ) once daily by mouth.

Potential patients must have been receiving a drug containing Donepezil for the last 6 months,